Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis

Worldwide, liver cancer is predicted to be the fourth most common cause of cancer-related mortality, accounting for an estimated 782,000 deaths in 2018, with most liver cancers being hepatocellular carcinoma (HCC).[1] There are, however, global differences in HCC incidence and trends, with Eastern and Southeast Asia having among the highest incidence of liver cancer.[1] This difference in HCC incidence between Asian and non-Asian regions is related to the high incidence of chronic viral hepatitis in Asia.

Source: Journal of Hepatology - June 5, 2019 Category: Gastroenterology Authors: Thomas Yau, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Yoon-Koo Kang, Ming-Mo Hou, Kazushi Numata, Winnie Yeo, Akhil Chopra, Masafumi Ikeda, Ryoko Kuromatsu, Michihisa Moriguchi, Yee Chao, Huanyu Zhao, Jeffrey Anderson, Christine Dela Cruz, Masatoshi Kudo Source Type: research